Publications

Around the world, procurement processes—which are vital to ensuring an affordable, reliable, and high-quality supply of health products—remain fraught with obstacles.

As the pandemic accelerates, governments must also protect other essential health services. Already, there have been numerous reports of disrupted access to services ranging from labor and delivery and immunization to HIV and tuberculosis care to dialysis and cancer treatment—most notably in countries with strict lockdowns. Initial estimates paint a grim picture of the potential magnitude of negative impacts on health outcomes due to these disruptions.

There have been impressive gains in global health over the past 20 years, with millions of lives saved through expanded access to essential medicines and other health products. But behind these successes is an unacceptable reality: in many low- and middle-income countries, lifesaving health products are either unavailable or beyond the reach of the people who need them most.

Gavi’s mission—saving children’s lives and protecting people’s health by increasing equitable use of vaccines—remains highly relevant. Gavi 5.0 needs a new model to deliver on its laudable mission. This overview note lays out five challenges and summarizes some of our ideas to address them; backing up each is a standalone note that provides greater detail and options for action.

Drawing on a range of political, economic, and social trends, this paper envisions how the global landscape might change between now and 2030, with a focus on the implications for global health, particularly the procurement of health products.

In October, world leaders renewed their commitment to Primary Health Care. Now is an opportune time to identify lessons learned and key challenges from the past 40 years, and to acknowledge the work that remains to be done to make vision reality.

Today, politicians are under growing pressure to squeeze more out of every dollar and guarantee greater access to better, more affordable healthcare for their citizens. In such a resource-constrained environment, wasting trillions of dollars on health every year is not viable. This note provides an overview of some of the approaches and policy options that the National Health Service in England has been using to maximise value for money.

With aid budgets shrinking and even low-income countries increasingly faced with cofinancing requirements, this is the right time for global health funders such as the Global Fund and their donors to formally introduce Health Technology Assessment (HTA), both at the central operations level and at the national or regional level in recipient countries. In this CGD Note, we explain why introducing HTA is a good idea. Specifically, we outline six benefits that the application of HTA could bring to the Global Fund, the countries it supports, and the broader global health community.